Literature DB >> 17239629

Epilepsy and seropositivity rates of Toxocara canis and Toxoplasma gondii.

Ali Akyol1, Banu Bicerol, Sema Ertug, Hatice Ertabaklar, Nefati Kiylioglu.   

Abstract

PURPOSE: Increased seropositivity for Toxoplasma gondii and Toxocara canis have been observed in epileptic patients. Our aim is to determine whether there is any relationship between these agents and epilepsy in our cryptogenic epilepsy group.
MATERIAL AND METHODS: We studied specific IgG antibodies against T. gondii and T. canis in 100 cryptogenic epileptic patients and 50 healthy volunteers that had no history of epilepsy in their first degree relatives. We studied T. gondii and T. canis-specific IgG antibody serum levels and compared the values of these two groups. RESULT: We found similar T. gondii and T. canis serum IgG antibodies in patients with cryptogenic epilepsy and in the control group, even though the control group included more animal owners.
CONCLUSION: We did not show any relationships between epilepsy and positive T. gondii and T. canis serology in our epileptic patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17239629     DOI: 10.1016/j.seizure.2006.12.008

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  15 in total

1.  Understanding Toxoplasmosis in the United States Through "Large Data" Analyses.

Authors:  Joseph Lykins; Kanix Wang; Kelsey Wheeler; Fatima Clouser; Ashtyn Dixon; Kamal El Bissati; Ying Zhou; Christopher Lyttle; Andrey Rzhetsky; Rima McLeod
Journal:  Clin Infect Dis       Date:  2016-06-26       Impact factor: 9.079

2.  Recurrent headaches may be caused by cerebral toxoplasmosis.

Authors:  Joseph Prandota; Anna Gryglas; Aleksander Fuglewicz; Agata Zesławska-Faleńczyk; Barbara Ujma-Czapska; Leszek Szenborn; Janusz Mierzwa
Journal:  World J Clin Pediatr       Date:  2014-08-08

Review 3.  Epidemiology, causes, and treatment of epilepsy in sub-Saharan Africa.

Authors:  Awa Ba-Diop; Benoît Marin; Michel Druet-Cabanac; Edgard B Ngoungou; Charles R Newton; Pierre-Marie Preux
Journal:  Lancet Neurol       Date:  2014-10       Impact factor: 44.182

Review 4.  Do helminths cause epilepsy?

Authors:  R G Wagner; C R Newton
Journal:  Parasite Immunol       Date:  2009-11       Impact factor: 2.280

5.  Toxoplasma gondii actively inhibits neuronal function in chronically infected mice.

Authors:  Fahad Haroon; Ulrike Händel; Frank Angenstein; Jürgen Goldschmidt; Peter Kreutzmann; Holger Lison; Klaus-Dieter Fischer; Henning Scheich; Wolfram Wetzel; Dirk Schlüter; Eike Budinger
Journal:  PLoS One       Date:  2012-04-18       Impact factor: 3.240

Review 6.  Toxocariasis and epilepsy: systematic review and meta-analysis.

Authors:  Graziella Quattrocchi; Alessandra Nicoletti; Benoit Marin; Elisa Bruno; Michel Druet-Cabanac; Pierre-Marie Preux
Journal:  PLoS Negl Trop Dis       Date:  2012-08-14

Review 7.  Toxoplasmosis and epilepsy--systematic review and meta analysis.

Authors:  Edgard B Ngoungou; Devender Bhalla; Amandine Nzoghe; Marie-Laure Dardé; Pierre-Marie Preux
Journal:  PLoS Negl Trop Dis       Date:  2015-02-19

8.  Investigation of anti-Toxocara antibodies in epileptic patients and comparison of two methods: ELISA and Western blotting.

Authors:  Mohammad Zibaei; Farzaneh Firoozeh; Parviz Bahrami; Seyed Mahmoud Sadjjadi
Journal:  Epilepsy Res Treat       Date:  2013-04-22

9.  Latent toxoplasmosis and human.

Authors:  A Dalimi; A Abdoli
Journal:  Iran J Parasitol       Date:  2012       Impact factor: 1.012

10.  Exposure to multiple parasites is associated with the prevalence of active convulsive epilepsy in sub-Saharan Africa.

Authors:  Gathoni Kamuyu; Christian Bottomley; James Mageto; Brett Lowe; Patricia P Wilkins; John C Noh; Thomas B Nutman; Anthony K Ngugi; Rachael Odhiambo; Ryan G Wagner; Angelina Kakooza-Mwesige; Seth Owusu-Agyei; Kenneth Ae-Ngibise; Honorati Masanja; Faith H A Osier; Peter Odermatt; Charles R Newton
Journal:  PLoS Negl Trop Dis       Date:  2014-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.